CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.

Sanofi’s last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5bn agreement to buy vaccine firm Dynavax.

Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi

Companies that have voluntarily agreed to drug pricing deals with the White House appear to be exempt from two new CMS demonstration programs that have

Plus, news about BioMarin and Cassava. 💊 Gilead opts into Assembly Bio’s genital herpes programs: As a result, Gilead will pay Assembly $35 million based